Patents by Inventor LAURENCE GOFFIN

LAURENCE GOFFIN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies specific for MMP9
    Patent number: 10364296
    Abstract: The present invention relates to new proteins that bind to MMP9 and comprise at least one fragment of a heavy chain variable region and/or at least one fragment of a light chain variable region of an antibody. In particular, the MMP9 binding proteins according to the invention are able to neutralize MMP9 activity and are useful in the prevention and/or treatment of inflammatory and/or autoimmune diseases or cancers. In particular, the MMP9 binding proteins according to the invention are useful in diagnosis of MMP9-related disorders.
    Type: Grant
    Filed: August 13, 2015
    Date of Patent: July 30, 2019
    Assignees: CALYPSO BIOTECH SA, MERCK PATENT GMBH
    Inventors: Yolande Chvatchko Missotten, Laurence Goffin, Olivier Leger, Steven M. Dunn, Christine Power, Kinsey Maundrell
  • Lactococcus lactis producing TSLP or IL-25 and their uses as probiotics and therapeutics
    Patent number: 10238697
    Abstract: The present invention relates to recombinant Lactococcus lactis bacteria expressing and secreting TSLP or IL-25 or a combination thereof, and their use as probiotics or therapeutic agents, especially for use in the treatment of inflammatory diseases and disorders.
    Type: Grant
    Filed: April 12, 2016
    Date of Patent: March 26, 2019
    Assignee: ARES TRADING S.A.
    Inventors: Philippe Langella, Jean-Marc Chatel, Luis Bermudez-Humaran, Camille Aubry, Laurence Goffin, Simone Favre-Zimmerli, Yolande Chvatchko
  • LACTOCOCCUS LACTIS PRODUCING TSLP OR IL-25 AND THEIR USES AS PROBIOTICS AND THERAPEUTICS
    Publication number: 20180104285
    Abstract: The present invention relates to recombinant Lactococcus lactis bacteria expressing and secreting TSLP or IL-25 or a combination thereof, and their use as probiotics or therapeutic agents, especially for use in the treatment of inflammatory diseases and disorders.
    Type: Application
    Filed: April 12, 2016
    Publication date: April 19, 2018
    Inventors: PHILIPPE LANGELLA, JEAN-MARC CHATEL, LUIS BERMUDEZ-HUMARAN, CAMILLE AUBRY, LAURENCE GOFFIN, SIMONE FAVRE-ZIMMERLI, YOLANDE CHVATCHKO
  • ANTIBODIES SPECIFIC FOR MMP9
    Publication number: 20170233495
    Abstract: The present invention relates to new proteins that bind to MMP9 and comprise at least one fragment of a heavy chain variable region and/or at least one fragment of a light chain variable region of an antibody. In particular, the MMP9 binding proteins according to the invention are able to neutralize MMP9 activity and are useful in the prevention and/or treatment of inflammatory and/or autoimmune diseases or cancers. In particular, the MMP9 binding proteins according to the invention are useful in diagnosis of MMP9-related disorders.
    Type: Application
    Filed: August 13, 2015
    Publication date: August 17, 2017
    Inventors: YOLANDE CHVATCHKO MISSOTTEN, LAURENCE GOFFIN, OLIVIER LEGER, STEVEN M. DUNN, CHRISTINE POWER, KINSEY MAUNDRELL